You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 404 ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC)

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
404 ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Lee K, Chung H, Kim WS, et al
404 ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC)
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0404